The company's BlueLeaf(TM) Endovenous Valve Formation System is a non-implantable, catheter-based therapy that creates new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their hearts. This addresses the underlying cause of painful venous stasis ulcers and other costly and devastating symptoms caused by deep vein valve failure, which affects millions of Americans. Founded in 2011 and based in South San Francisco, InterVene aims to provide the first effective and widely utilized therapy for patients suffering from the painful and costly symptoms of Chronic Venous Insufficiency (CVI) due to deep vein reflux (DVR). The company has developed a range of medical devices that enable doctors to form new vein valves out of a patient's own vein wall tissue. InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation.